A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Leukemia

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/leu.2008.271PMID 18830257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The B7 Family and Cancer Therapy: Costimulation and Coinhibition

  2007cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Supraagonistic, bispecific single‐chain antibody purified from the serum of cloned, transgenic cows induces T‐cell‐mediated killing of glioblastoma cells in vitro and in vivo

  2005cited by this paper
• Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases

  2005cited by this paper
• Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing.

  2004cited by this paper
• Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia

  2004cited by this paper
• Rapid recovery from T lymphopenia by CD28 superagonist therapy.

  2003cited by this paper
• A recombinant bispecific single‐chain antibody induces targeted, supra‐agonistic CD28‐stimulation and tumor cell killing

  2003cited by this paper
• Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma.

  1999cited by this paper
• CD28‐mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28

  1997cited by this paper
• Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia.

  1996cited by this paper
• Target cell‐induced T cell activation with bi‐ and trispecific antibody fragments

  1991cited by this paper
• Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes.

  1991cited by this paper
• Chronic lymphocytic leukemia: new insights into biology and therapy.

  1990cited by this paper
• T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease.

  1989cited by this paper
• Defective helper function of purified T4 cells and excessive suppressor activity of purified T8 cells in patients with B-cell chronic lymphocytic leukemia. T4 suppressor effector cells are present in certain patients.

  1988cited by this paper
• Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.

  1987cited by this paper
• Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies.

  1982cited by this paper

• The present and future of bispecific antibodies for cancer therapy

  2024cites this paper
• Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells

  2024cites this paper
• A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023

  2024cites this paper
• Biology and Clinical Evaluation of T/NK Cell Engagers

  2022cites this paper
• Bispecific antibodies for immune cell retargeting against cancer

  2022cites this paper
• Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

  2021influential citation
• Therapeutic Antibodies and Immunologic Conjugates

  2020cites this paper
• A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.

  2019cites this paper
• Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.

  2019cites this paper
• Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

  2018cites this paper
• A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity

  2017cites this paper
• Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.

  2015cites this paper
• Multifunctional receptor-targeting antibodies for cancer therapy.

  2015cites this paper
• Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.

  2015cites this paper
• Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle

  2015cites this paper
• Bifunctional Antibodies: Preclinical and Clinical Applications

  2014cites this paper
• Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

  2014cites this paper
• Multi-Specific Antibodies for Cancer Immunotherapy

  2014cites this paper
• Development trends for generation of single-chain antibody fragments

  2014cites this paper
• Cancer T cell immunotherapy with bispecific antibodies and chimeric antigen receptors.

  2013cites this paper
• The intriguing options of multispecific antibody formats for treatment of cancer.

  2013cites this paper
• Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics

  2012cites this paper
• Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

  2012cites this paper
• Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs

  2012cites this paper
• WITHDRAWN: Tetravalent Bispecific Single-Chain Fv Antibodies for Lysis of Leukemia Cells by Autologous T Cells.

  2012cites this paper
• Bispecific Antibodies and Immune Therapy Targeting

  2011cites this paper
• Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.

  2011cites this paper
• Effector Cell Recruitment by Bispecific Antibodies

  2011cites this paper
• TRISPECIFIC THERAPEUTICS AGAINST ACUTE MYELOID LEUKAEMIA

  2011cites this paper
• Targeting T Cells with Bispecific Antibodies for Cancer Therapy

  2011cites this paper
• Generation of recombinant single-chain antibodies neutralizing the cytolytic activity of vaginolysin, the main virulence factor of Gardnerella vaginalis

  2011cites this paper
• Antibodies in single-chain format against tumour-associated antigens: present and future applications.

  2010cites this paper
• Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

  2010cites this paper
• Bispecific Antibodies for Cancer Immunotherapy

  2010cites this paper
• Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

  2010cites this paper
• Bispecific antibodies for cancer therapy

  2009cites this paper
• Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

  2009cites this paper